Pure Global AI
NCT06240143Not yet recruiting

Intradermal Ipilimumab and Nivolumab in High Risk Stage II Melanoma

Multicenter Phase 1b/2 Trial Testing Neoadjuvant Intradermal Ipilimumab and Nivolumab in High Risk Stage II Melanoma - MARIANE
The Netherlands Cancer InstitutePhase 1/2ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Melanoma
Drug/Device/Intervention
Ipilimumab
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
The Netherlands Cancer Institute
Location
Amsterdam,Amsterdam,Groningen,Leiden,Rotterdam,Utrecht, Netherlands
Timeline & enrollment
Phase
Phase 1/2
Start date
Feb 01, 2024
End date
May 01, 2026
Enrollment
80 participants
Primary outcome

Feasibility,Effectivity

Summary

This open label, single country trial will test if local injection of low-dose ipilimumab and
 nivolumab, is safe and reduces the sentinel node positivity in high-risk stage II melanoma
 patients.

ICD-10 classifications
Malignant melanoma of skinMelanoma in situ, unspecifiedMelanoma in situMelanoma and other malignant neoplasms of skinMalignant neoplasm: Malignant melanoma of skin, unspecified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06240143
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06240143 through Pure Global AI's free database. This Phase 1/2 trial is sponsored by The Netherlands Cancer Institute and is currently Not yet recruiting. The study focuses on Melanoma. Target enrollment is 80 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.